4 years ago
NeoPhore Raises £15.2 Million to Develop Next-Generation Cancer Immunotherapies
Cambridge-based biotech startup NeoPhore has raised £15.2 million in a Series B funding round to advance its drug discovery pipeline for novel cancer treatments
The company focuses on developing therapies that stimulate the immune system to fight cancer by creating neoantigens
The funding round was led by Claris Ventures, with participation from other investors.
ProblemHealthcare
"Cancer is a deadly disease that affects millions of people worldwide. Current treatments often have severe side effects and are not always effective. There is a need for new and innovative therapies that can target cancer cells more effectively and with fewer side effects."
Solution
"NeoPhore is developing a new class of drugs that stimulate the immune system to fight cancer. These drugs work by targeting the MMR pathway, which is a key regulator of the immune response. By inhibiting the MMR pathway, NeoPhore's drugs force cancer cells to reveal themselves to the immune system, making them more vulnerable to attack. This approach has the potential to lead to more effective and durable cancer treatments."
